Author

Meret Hahn

Heidelberg University

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1

Frequent Co-Authors

Alessa Klär· 1 shared Alexander StreueriD· 1 shared Ali DarwichiD· 1 shared Ann‐Christin Belzer· 1 shared Daniel NowakiD· 1 shared Eva AltrockiD· 1 shared Felicitas RappiD· 1 shared Franziska Hofmann· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Alessa Klär

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Primary CD34+ cells of patients with VEXAS syndrome are highly sensitive to targeted treatment with TAK-243 and pevonedistat

Daniel Nowak, Marie Demmerle, Alessa Klär, Alexander Streuer, Vladimir Riabov, Eva Altrock, Felicitas Rapp, Ann‐Christin Belzer, Teresa Klink, Meret Hahn, Franziska Hofmann, Verena Nowak, Nadine Weimer, Julia Obländer, Iris Palme, , Nanni Schmitt

This study shows that VEXAS patient-derived CD34+ cells are more sensitive to TAK-243 and pevonedistat than MDS and healthy controls, suggesting potential targeted therapy.

bioRxiv · May 22, 2025 · PreprintCancer Biology